TribLIVE

| Business


 
Larger text Larger text Smaller text Smaller text | Order Photo Reprints

U.S. jury hits Takeda, Eli Lilly with $9 billion penalty

On the Grid

From the shale fields to the cooling towers, Trib Total Media covers the energy industry in Western Pennsylvania and beyond. For the latest news and views on gas, coal, electricity and more, check out On the Grid today.

By The Associated Press
Tuesday, April 8, 2014, 7:21 a.m.
 

TOKYO — A U.S. jury ordered Takeda Pharmaceutical Co. and Eli Lilly to pay $9 billion in punitive damages over a diabetes medicine linked to cancer, but Japan's biggest drugmaker said Tuesday it will “vigorously challenge” the decision.

The U.S District Court in western Louisiana decided a $6 billion penalty for Takeda and $3 billion for its business partner and co-defendant Eli Lilly. It also ordered $1.5 million in compensatory damages in favor of the plaintiff.

The legal fight turned on whether Actos, which is a drug used to treat type-two diabetes, caused a patient's bladder cancer and by implication was responsible for other cases of the cancer.

Takeda and Eli Lilly are facing numerous other lawsuits over the drug, which allege failure to warn about side effects and concealment of its health risks.

Kenneth Greisman, a general counsel at Takeda, said in a statement that the evidence does not support a link between Actos and bladder cancer.

“Takeda respectfully disagrees with the verdict, and we intend to vigorously challenge this outcome through all available legal means, including possible post-trial motions and an appeal,” he said.

Punitive damages are often reduced on appeal.

In June 2011, the U.S. Food and Drug Administration published a drug safety update on Actos, which said there was a 40 percent increase in bladder cancer risk in people who used the drug for longer than a year. It required that the cancer risk be added to the medication's warning label. Actos has been sold since 1999.

Actos comes with warnings about various serious side effects, including liver problems and higher risk of broken bones.

A former Takeda medical reviewer, Helen Ge, alleged in a U.S. District Court filing in 2012 that the Japanese drugmaker understated the number of bladder cancer cases possibly linked to Actos in its disclosures to the FDA.

Shares of Osaka-based Takeda tanked on the Tokyo Stock Exchange, closing down 5.2 percent.

 

 
 


Show commenting policy

Most-Read Business Headlines

  1. First Niagara sets aside $45 million
  2. Mortgage rate slide’s impact could be minimal
  3. Education Management removes itself from Nasdaq listing
  4. PUC approves Columbia Gas pipeline extensions program for homeowners
  5. EQT Corp. boosts profits despite lower gas prices
  6. Rule to close coal royalty loophole
  7. World’s 1st carbon capture power plant switches on in Canada
  8. Highmark seeks double-digit increase for more benefits, heavy use
  9. Falling fuel prices help airlines — not fliers
  10. Toy sellers to enhance marketing as holidays approach
  11. Natrona Bottling Co. keeps soda pop operation focused on craft, taste
Subscribe today! Click here for our subscription offers.